PubRank

Ivan Ischenko

Author PubWeight™ 13.39‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma. Mol Cancer Res 2009 1.33
2 Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood 2005 1.17
3 EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells. Biol Chem 2009 1.15
4 Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma. Ann Surg 2009 1.08
5 Cancer stem cells and angiogenesis. Int J Dev Biol 2011 1.06
6 The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1. J Cell Biochem 2007 0.97
7 Risk factors for surgical complications in distal pancreatectomy. Am J Surg 2010 0.96
8 Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. Int J Cancer 2010 0.89
9 Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice. Int J Mol Med 2005 0.86
10 Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Anticancer Drugs 2007 0.86
11 Investigation of the marine compound spongistatin 1 links the inhibition of PKCalpha translocation to nonmitotic effects of tubulin antagonism in angiogenesis. FASEB J 2008 0.84
12 The marine compound spongistatin 1 targets pancreatic tumor progression and metastasis. Int J Cancer 2010 0.83
13 Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis. Target Oncol 2014 0.80
14 Matuzumab short-term therapy in experimental pancreatic cancer: prolonged antitumor activity in combination with gemcitabine. Clin Cancer Res 2008 0.76